Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Margaux GeierRenaud DescourtRomain CorreGuillaume LéveillerRégine LamyÉric GoarantJean-Louis BizecCyril BernierGilles QuéréKarim AmraneElisabeth GayeFrançois LuciaEmilie BurteChristos ChouaidGilles RobinetPublished in: Cancer medicine (2020)
In real-life, prolonged nivolumab use provided long-term benefit with 16.6% 3-year OS and 25% LTSs. Survival tended to be prolonged with nivolumab continued beyond 2 years. Prospective randomized trials with adequate design are needed.